Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Similar articles for PubMed (Select 23371912)

1.
2.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

3.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

4.

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jul 1;17(13):4425-38. doi: 10.1158/1078-0432.CCR-10-3339. Epub 2011 May 27.

5.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.

PMID:
18696232
6.

Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.

Rogers SJ, Box C, Chambers P, Barbachano Y, Nutting CM, Rhŷs-Evans P, Workman P, Harrington KJ, Eccles SA.

J Pathol. 2009 May;218(1):122-30. doi: 10.1002/path.2515.

PMID:
19197951
8.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R.

Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.

9.

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.

Clin Cancer Res. 2010 Feb 15;16(4):1159-69. doi: 10.1158/1078-0432.CCR-09-2353. Epub 2010 Feb 9.

10.

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A.

J Cell Physiol. 2011 Sep;226(9):2378-90. doi: 10.1002/jcp.22574.

PMID:
21660961
11.

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.

Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF.

Br J Cancer. 2009 Mar 24;100(6):941-9. doi: 10.1038/sj.bjc.6604937. Epub 2009 Feb 24.

12.

Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor.

Sweeny L, Liu Z, Lancaster W, Hart J, Hartman YE, Rosenthal EL.

Laryngoscope. 2012 Jul;122(7):1539-44. doi: 10.1002/lary.23266. Epub 2012 Mar 27.

13.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

14.

Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.

Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M.

J Thorac Oncol. 2011 May;6(5):864-74.

PMID:
21774103
16.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

17.

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Mueller KL, Hunter LA, Ethier SP, Boerner JL.

Cancer Res. 2008 May 1;68(9):3314-22. doi: 10.1158/0008-5472.CAN-08-0132.

18.

Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S.

Endocrinology. 2005 Mar;146(3):1145-53. Epub 2004 Nov 24.

PMID:
15564323
19.

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.

Clin Cancer Res. 2006 Jan 15;12(2):617-25.

20.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

PMID:
19804422
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk